Search

Your search keyword '"Garg, Mamta"' showing total 216 results
Start Over Author "Garg, Mamta" Language english
216 results on '"Garg, Mamta"'

1. Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial

Author

Cook, Gordon, Ashcroft, A John, Senior, Ethan, Olivier, Catherine, Hockaday, Anna, Richards, Jeanine, Cavenagh, Jamie D, Snowden, John A, Drayson, Mark T, de Tute, Ruth, Roberts, Lesley, Owen, Roger G, Yong, Kwee, Garg, Mamta, Boyd, Kevin, Sati, Hamdi, Gillson, Sharon, Cook, Mark, Cairns, David A, and Parrish, Christopher

Published
2024
Full Text
View/download PDF

4. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

Author

Mateos, Maria-Victoria, Dimopoulos, Meletios A., Cavo, Michele, Suzuki, Kenshi, Knop, Stefan, Doyen, Chantal, Lucio, Paulo, Nagy, Zsolt, Pour, Ludek, Grosicki, Sebastian, Crepaldi, Andre, Liberati, Anna Marina, Campbell, Philip, Yoon, Sung-Soo, Iosava, Genadi, Fujisaki, Tomoaki, Garg, Mamta, Iida, Shinsuke, Bladé, Joan, Ukropec, Jon, Pei, Huiling, Van Rampelbergh, Rian, Kudva, Anupa, Qi, Ming, and San-Miguel, Jesus

Published
2021
Full Text
View/download PDF

5. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Author

Moreau, Philippe, Dimopoulos, Meletios-Athanasios, Mikhael, Joseph, Yong, Kwee, Capra, Marcelo, Facon, Thierry, Hajek, Roman, Spicka, Ivan, Baker, Ross, Kihyun, Kim, Martinez, Gracia, Chang-Ki, Min, Pour, Ludek, Leleu, Xavier, Oriol, Albert, Youngil, Koh, Suzuki, Kenshi, Martin, Tom, Quach, Hang, Lim, Andrew, Crowther, Helen, Sia, Hanlon, Hulin, Cyrille, Mohty, Mohamad, Mikala, Gabor, Nagy, Zsolt, Reinoso Segura, Marta, Rosinol, Laura, Yagci, Munci, Turgut, Mehmet, Garg, Mamta, Parmar, Gurdeep, Augustson, Brad, Castro, Nelson, Crusoe, Edvan, Pika, Tomas, Delimpasi, Sosana, Ishizawa, Kenichi, George, Anup, Konstantinova, Tatiana, De La Rubia, Javier, Sung-Hyun, Kim, Maiolino, Angelo, Reiman, Anthony, LeBlanc, Richard, Ito, Shigeki, Tanaka, Junji, Luchinin, Alexander, Kryuchkova, Irina, Martinez, Joaquin, Shustik, Jesse, Karlin, Lionel, Symeonidis, Anargyros, Egyed, Miklos, Petrini, Mario, Cavo, Michele, Uchiyama, Michihiro, Blacklock, Hilary, Arat, Mutlu, Griffin, James, Hunter, Hannah, Buck, Tonda, Anagnostopoulos, Achilles, Konstantopoulos, Konstantinos, Masszi, Tamas, Bringhen, Sara, Gamberi, Barbara, Kawano, Yawara, Jin Seok, Kim, Ozdogu, Hakan, Ozkalemkas, Fahir, Špička, Ivan, Kim, Kihyun, Min, Chang-Ki, Koh, Youngil, Risse, Marie-Laure, Asset, Gaelle, Macé, Sandrine, and Martin, Thomas

Published
2021
Full Text
View/download PDF

6. Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm

Author

Salisbury, Richard A., Curto-Garcia, Natalia, O’Sullivan, Jennifer, Chen, Frederick, Polzella, Paolo, Godfrey, Anna L., Russell, James, Knapper, Steven, Willan, John, Frewin, Rebecca, Joshi, Shivani, Arami, Siamak, Burns, Sarah, Teh, Chun Huat, Wadelin, Frances, Dhanapal, Jaymathi, Neelakantan, Pratap, Milojkovic, Dragana, Psaila, Beth, Szydlo, Richard, Francis, Sebastian, Cargo, Catherine, Jain, Manish, McGregor, Andrew, Wallis, Louise, Duncombe, Andrew, Hussein, Hayder, Dyer, Peter, Munro, Laura, Bond, Lee, McMullin, Mary Frances, Somervaille, Tim C. P., Garg, Mamta, Sekhar, Mallika, Harrison, Claire, Mead, Adam J., and Innes, Andrew J.

Published
2021
Full Text
View/download PDF

8. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Author

Grosicki, Sebastian, Simonova, Maryana, Spicka, Ivan, Pour, Ludek, Kriachok, Iryrna, Gavriatopoulou, Maria, Pylypenko, Halyna, Auner, Holger W, Leleu, Xavier, Doronin, Vadim, Usenko, Ganna, Bahlis, Nizar J, Hajek, Roman, Benjamin, Reuben, Dolai, Tuphan K, Sinha, Dinesh K, Venner, Christopher P, Garg, Mamta, Gironella, Mercedes, Jurczyszyn, Artur, Robak, Pawel, Galli, Monica, Wallington-Beddoe, Craig, Radinoff, Atanas, Salogub, Galina, Stevens, Don A, Basu, Supratik, Liberati, Anna M, Quach, Hang, Goranova-Marinova, Vesselina S, Bila, Jelena, Katodritou, Eirini, Oliynyk, Hanna, Korenkova, Sybiryna, Kumar, Jeevan, Jagannath, Sundar, Moreau, Phillipe, Levy, Moshe, White, Darrell, Gatt, Moshe E, Facon, Thierry, Mateos, Maria V, Cavo, Michele, Reece, Donna, Anderson, Larry D, Jr, Saint-Martin, Jean-Richard, Jeha, Jacqueline, Joshi, Anita A, Chai, Yi, Li, Lingling, Peddagali, Vishnuvardhan, Arazy, Melina, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G, Dimopoulos, Meletios A, Richardson, Paul G, and Delimpasi, Sosana

Published
2020
Full Text
View/download PDF

9. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

Author

Mateos, Maria-Victoria, Cavo, Michele, Blade, Joan, Dimopoulos, Meletios A, Suzuki, Kenshi, Jakubowiak, Andrzej, Knop, Stefan, Doyen, Chantal, Lucio, Paulo, Nagy, Zsolt, Pour, Ludek, Cook, Mark, Grosicki, Sebastian, Crepaldi, Andre, Liberati, Anna Marina, Campbell, Philip, Shelekhova, Tatiana, Yoon, Sung-Soo, Iosava, Genadi, Fujisaki, Tomoaki, Garg, Mamta, Krevvata, Maria, Chen, Ying, Wang, Jianping, Kudva, Anupa, Ukropec, Jon, Wroblewski, Susan, Qi, Ming, Kobos, Rachel, and San-Miguel, Jesus

Published
2020
Full Text
View/download PDF

10. Re-Searching Secondary Teacher Trainees in Distance Education and Face-to-Face Mode: Study of Their Background Variables, Personal Characteristics and Academic Performance

Author

Garg, Mamta and Gakhar, Sudesh

Abstract

The present investigation was conducted to describe and compare the background variables, personal characteristics and academic performance of secondary teacher trainees in distance education and face-to-face mode. The results indicated that teacher trainees in distance education differed from their counterparts in age, marital status, sex and socio-economic status. Distance trainees outperformed the on-campus trainees on their preference for left-hemispheric styles of learning and thinking, budgeting time, learning motivation, overall study habits, academic motivation, attitude towards education, work methods, interpersonal relations, and on their perception about relevance of course content of theory papers in B.Ed., but on-campus trainees outperformed distance trainees on preference for right-hemispheric learning styles, need for achievement, motivation for sports, attitude towards teaching profession, child-centered practices, teachers, overall attitude towards teaching along with their perception for development of teaching skills and attitude, personality development during B.Ed. course. In academic performance distance trainees lag behind the on-campus trainee in their marks in theory papers, skills in teaching and in aggregate. (Contains 13 tables.)

Published
2011

11. Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial

Author

Knop, Stefan, Mateos, Maria-Victoria, Dimopoulos, Meletios A., Suzuki, Kenshi, Jakubowiak, Andrzej, Doyen, Chantal, Lucio, Paulo, Nagy, Zsolt, Usenko, Ganna, Pour, Ludek, Cook, Mark, Grosicki, Sebastian, Crepaldi, Andre, Liberati, Anna Marina, Campbell, Philip, Shelekhova, Tatiana, Yoon, Sung-Soo, Losava, Genadi, Fujisaki, Tomoaki, Garg, Mamta, Wang, Jianping, Wroblewski, Susan, Kudva, Anupa, Gries, Katharine S., Fastenau, John, San-Miguel, Jesus, and Cavo, Michele

Published
2021
Full Text
View/download PDF

12. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

Author

Mateos, Maria V., Gavriatopoulou, Maria, Facon, Thierry, Auner, Holger W., Leleu, Xavier, Hájek, Roman, Dimopoulos, Meletios A., Delimpasi, Sosana, Simonova, Maryana, Špička, Ivan, Pour, Ludĕk, Kriachok, Iryna, Pylypenko, Halyna, Doronin, Vadim, Usenko, Ganna, Benjamin, Reuben, Dolai, Tuphan K., Sinha, Dinesh K., Venner, Christopher P., Garg, Mamta, Stevens, Don A., Quach, Hang, Jagannath, Sundar, Moreau, Philippe, Levy, Moshe, Badros, Ashraf Z., Anderson, Jr., Larry D., Bahlis, Nizar J., Cavo, Michele, Chai, Yi, Jeha, Jacqueline, Arazy, Melina, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., Richardson, Paul G., and Grosicki, Sebastian

Published
2021
Full Text
View/download PDF

13. Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

Author

Jackson, Graham H, Davies, Faith E, Pawlyn, Charlotte, Cairns, David A, Striha, Alina, Collett, Corinne, Waterhouse, Anna, Jones, John R, Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D, Karunanithi, Kamaraj, Lindsay, Jindriska, Wilson, Jamie N, Jenner, Matthew W, Cook, Gordon, Kaiser, Martin F, Drayson, Mark T, Owen, Roger G, Russell, Nigel H, Gregory, Walter M, and Morgan, Gareth J

Published
2019
Full Text
View/download PDF

14. Guideline for the Management of Conception and Pregnancy in Thalassaemia Syndromes: A British Society for Haematology Guideline.

Author

Shah, Farrukh T., Nicolle, Sarah, Garg, Mamta, Pancham, Shivan, Lieberman, Gidon, Anthony, Karen, and Mensah, Amma Kyei

Subjects
THALASSEMIA, MEDICAL personnel, HEMATOLOGY, PREGNANCY, SYNDROMES
Abstract

Summary: This comprehensive guideline, developed by a representative group of UK‐based medical experts specialising in haemoglobinopathies, addresses the management of conception and pregnancy in patients with thalassaemia. A systematic search of PubMed and EMBASE using specific keywords, formed the basis of the literature review. Key terms included "thalassaemia," "pregnancy," "Cooley's anaemia," "Mediterranean anaemia," and others, covering aspects such as fertility, iron burden and ultrasonography. The guideline underwent rigorous review by prominent organisations, including the Endocrine Society, the Royal College of Obstetricians and Gynaecologists (RCOG), the United Kingdom Thalassaemia Society and the British Society of Haematology (BSH) guideline writing group. Additional feedback was solicited from a sounding board of UK haematologists, ensuring a thorough and collaborative approach. The objective of the guideline is to equip healthcare professionals with precise recommendations for managing conception and pregnancy in patients with thalassaemia. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Author

Bar, Daniel, Basso, Alfredo, Fantl, Dorotea, He, Simon, Horvath, Neomi, Lee, Cindy, Rowlings, Phillip, Taylor, Kerry, Spencer, Andrew, Cochrane, Tara, Kwok, Fiona, Ramanathan, Sundreswran, Agis, Hermine, Zojer, Niklas, Kentos, Alain, Offner, Fritz, Van Droogenbroeck, Jan, Wu, Ka Lung, Maiolino, Angelo, Martinez, Gracia, Zanella, Karla, Capra, Marcelo, Araújo, Sérgio, Gregora, Evzen, Hajek, Roman, Maisnar, Vladimir, Pour, Ludek, Scudla, Vlastimil, Spicka, Ivan, Abildgaard, Niels, Andersen, Niels, Jensen, Bo Amdi, Helleberg, Carsten, Plesner, Torben, Salomo, Morten, Svirskaite, Asta, Delarue, Richard, Moreau, Philippe, Blau, Igor, Goldschmidt, Hartmut, Schieferdecker, Aneta, Teleanu, Veronica, Munder, Markus, Röllig, Christoph, Salwender, Han-Juergen, Fuhrmann, Stephan, Weisel, Katja, Duerig, Jan, Zeis, Matthias, Klein, Stefan, Reimer, Peter, Schmidt, Christian, Scheid, Christof, Mayer, Karin, Hoffmann, Martin, Sosada, Markus, Dimopoulos, Athanasios, Delimpasi, Sosana, Kyrtsonis, Mary-Christine, Anagnostopoulos, Achilleas, Nagy, Zsolt, Illés, Árpád, Egyed, Miklós, Borbényi, Zita, Mikala, Gabor, Dally, Najib, Horowitz, Netanel, Gutwein, Odit, Nemets, Anatoly, Vaxman, Iuliana, Shvetz, Olga, Trestman, Svetlana, Ruchlemer, Rosa, Nagler, Arnon, Tadmor, Tamar, Rouvio, Ory, Preis, Meir, Gay, Francesca, Cavo, Michele, De Rosa, Luca, Musto, Pellegrino, Cafro, Anna, Tosi, Patrizia, Offidani, Massimo, Corso, Alessandro, Rossi, Giuseppe, Liberati, Anna Marina, Bosi, Alberto, Suzuki, Kenshi, Iida, Shinsuke, Nakaseko, Chiaki, Ishikawa, Takayuki, Matsumoto, Morio, Nagai, Hirokazu, Sunami, Kazutaka, Chou, Takaaki, Akashi, Koichi, Takezako, Naoki, Hagiwara, Shotaro, Eom, Hyeon Seok, Jo, Deog-Yeon, Kim, Jin Seok, Lee, Jae Hoon, Min, Chang Ki, Yoon, Sung Soo, Yoon, Dok Hyun, Kim, Kihyun, Zweegman, Sonja, Levin, Mark-David, Vellenga, Edo, Minnema, Monique, Schjesvold, Fredrik, Waage, Anders, Haukås, Einar, Grosicki, Sebastian, Pluta, Andrzej, Robak, Tadeusz, Marques, Herlander, Bergantim, Rui, Campilho, Fernando, Chng, Wee Joo, Goh, Yeow Tee, McDonald, Andrew, Rapoport, Bernado, Álvarez Rivas, Miguel Angel, De Arriba de La Fuente, Felipe, González Montes, Yolanda, Martin Sanchez, Jesus, Mateos, Maria Victoria, Oriol Rocafiguera, Albert, Rosinol, Laura, San Miguel, Jesús, Pérez de Oteyza, Jaime, Encinas, Cristina, Alegre-Amor, Adrian, López-Guía, Ana, Axelsson, Per, Carlson, Kristina, Stromberg, Olga, Hansson, Markus, Hveding Blimark, Cecile, Mueller, Rouven, Chen, Chih-Cheng, Liu, Ta-Chih, Huang, Shang-Yi, Wang, Po-Nan, Na Nakorn, Thanyaphong, Prayongratana, Kannadit, Beksac, Meral, Unal, Ali, Goker, Hakan, Sonmez, Mehmet, Korenkova, Sybiryna, Chaidos, Aristeidis, Oakervee, Heather, Sati, Hamdi, Benjamin, Reuben, Wechalekar, Ashutosh, Garg, Mamta, Kaiser, Martin, Ramasamy, Karthik, Cook, Gordon, Chantry, Andrew, Jenner, Matthew, Buadi, Francis, Berryman, Robert, Janakiram, Murali, Dimopoulos, Meletios A, Weisel, Katja Christina, Pluta, Agnieszka, Chng, Wee-Joo, Mateos, Maria-Victoria, Morgan, Gareth, Suryanarayan, Kaveri, Teng, Zhaoyang, Skacel, Tomas, Palumbo, Antonio, Dash, Ajeeta B, Gupta, Neeraj, Labotka, Richard, and Rajkumar, S Vincent

Published
2019
Full Text
View/download PDF

16. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

Author

Jackson, Graham H, Davies, Faith E, Pawlyn, Charlotte, Cairns, David A, Striha, Alina, Collett, Corinne, Hockaday, Anna, Jones, John R, Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D, Karunanithi, Kamaraj, Lindsay, Jindriska, Jenner, Matthew W, Cook, Gordon, Russell, Nigel H, Kaiser, Martin F, Drayson, Mark T, Owen, Roger G, Gregory, Walter M, and Morgan, Gareth J

Published
2019
Full Text
View/download PDF

17. Prevention and treatment of infection in patients with an absent or hypofunctional spleen: A British Society for Haematology guideline.

Author

Ladhani, Shamez N., Fernandes, Savio, Garg, Mamta, Borrow, Ray, de Lusignan, Simon, and Bolton‐Maggs, Paula H. B.

Subjects
SPLENECTOMY, INFECTION prevention, MEDICAL education, SPLEEN, HEMATOLOGY, DRUG resistance in microorganisms
Abstract

Summary: Guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen were published by the British Committee for Standards in Haematology in 1996 and updated in 2002 and 2011. With advances in vaccinations and changes in patterns of infection, the guidelines required updating. Key aspects included in this guideline are the identification of patients at risk of infection, patient education and information and immunisation schedules. This guideline does not address the non‐infective complications of splenectomy or functional hyposplenism (FH). This replaces previous guidelines and significantly revises the recommendations related to immunisation. Patients at risk include those who have undergone surgical removal of the spleen, including partial splenectomy and splenic embolisation, and those with medical conditions that predispose to FH. Immunisations should include those against Streptococcus pneumoniae (pneumococcus), Neisseria meningitidis (meningococcus) and influenza. Haemophilus influenzae type b (Hib) is part of the infant immunisation schedule and is no longer required for older hyposplenic patients. Treatment of suspected or proven infections should be based on local protocols and consider relevant anti‐microbial resistance patterns. The education of patients and their medical practitioners is essential, particularly in relation to the risk of serious infection and its prevention. Further research is required to establish the effectiveness of vaccinations in hyposplenic patients; infective episodes should be regularly audited. There is no single group ideally placed to conduct audits into complications arising from hyposplenism, highlighting a need for a national registry, as has proved very successful in Australia or alternatively, the establishment of appropriate multidisciplinary networks. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Real‐world efficacy of single‐agent belantamab mafodotin in relapsed systemic AL amyloidosis.

Author

Khwaja, Jahanzaib, Bomsztyk, Joshua, Atta, Maria, Bygrave, Ceri, Forbes, Adam, Durairaj, Senthil, Fernandes, Savio, Taylor, James, Paterson, Pamela, Brearton, Gillian, Crawley, Charles, Sheehy, Oonagh, Brown, Rachel, Soutar, Richard, Garg, Mamta, Rydzewski, Andrzej, Jamroziak, Krzysztof, Mahmood, Shameem, and Wechalekar, Ashutosh D.

Subjects
PLASMA cell diseases, AMYLOIDOSIS, ANTIBODY-drug conjugates
Abstract

Summary: Systemic light chain (AL) amyloidosis is a relapsing plasma cell disorder. Therapy is limited, particularly for triple‐class refractory disease. We report the use of belantamab mafodotin, a BCMA‐directed drug–antibody conjugate, for relapsed AL amyloidosis, including patients traditionally excluded from clinical trials. Thirty‐one patients were reviewed, with a median of three prior lines of therapy. The median follow‐up was 12 months (95% CI 4–19), and a median of five doses were delivered. The best haematological overall response rate was 71%, and the complete/very good partial response was 58%. Sixty‐eight percent had keratopathy and improved in all. Belantamab mafodotin has high efficacy and good tolerability in patients with relapsed AL amyloidosis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline.

Author

Kulasekararaj, Austin, Cavenagh, Jamie, Dokal, Inderjeet, Foukaneli, Theodora, Gandhi, Shreyans, Garg, Mamta, Griffin, Morag, Hillmen, Peter, Ireland, Robin, Killick, Sally, Mansour, Sahar, Mufti, Ghulam, Potter, Victoria, Snowden, John, Stanworth, Simon, Zuha, Roslin, and Marsh, Judith

Subjects
APLASTIC anemia, LEUKOCYTES, BLOOD platelet transfusion, HEMATOLOGY, STEM cell transplantation, YOUNG adults
Abstract

Summary: Pancytopenia with hypocellular bone marrow is the hallmark of aplastic anaemia (AA) and the diagnosis is confirmed after careful evaluation, following exclusion of alternate diagnosis including hypoplastic myelodysplastic syndromes. Emerging use of molecular cyto‐genomics is helpful in delineating immune mediated AA from inherited bone marrow failures (IBMF). Camitta criteria is used to assess disease severity, which along with age and availability of human leucocyte antigen compatible donor are determinants for therapeutic decisions. Supportive care with blood and platelet transfusion support, along with anti‐microbial prophylaxis and prompt management of opportunistic infections remain key throughout the disease course. The standard first‐line treatment for newly diagnosed acquired severe/very severe AA patients is horse anti‐thymocyte globulin and ciclosporin‐based immunosuppressive therapy (IST) with eltrombopag or allogeneic haemopoietic stem cell transplant (HSCT) from a matched sibling donor. Unrelated donor HSCT in adults should be considered after lack of response to IST, and up front for young adults with severe infections and a readily available matched unrelated donor. Management of IBMF, AA in pregnancy and in elderly require special attention. In view of the rarity of AA and complexity of management, appropriate discussion in multidisciplinary meetings and involvement of expert centres is strongly recommended to improve patient outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib

Author

Rampotas, Alex, Carter-Brzezinski, Luke, Somervaille, Tim C. P., Forryan, James, Panitsas, Fotios, Harrison, Claire, Witherall, Ruth, Innes, Andrew J., Wallis, Louise, Butt, Naumann M., Psaila, Bethan, Mead, Adam J., Carter, Matthew, Godfrey, Anna L., Laing, Heather, Garg, Mamta, Francis, Sebastian, Ewing, Joanne, Teh, Chun Huat, Cowen, Hannah Bibi, Dyer, Peter, McConville, Conall, Wadelin, Frances, Sahra, Ali, McGregor, Andrew, Kulakov, Elizabeth, McLornan, Donal P., and Lambert, Jonathan

Published
2024
Full Text
View/download PDF

21. The management of myelofibrosis: A British Society for Haematology Guideline.

Author

McLornan, Donal P., Psaila, Bethan, Ewing, Joanne, Innes, Andrew, Arami, Siamak, Brady, Jessica, Butt, Nauman M., Cargo, Catherine, Cross, Nicholas C. P., Francis, Sebastian, Frewin, Rebecca, Garg, Mamta, Godfrey, Anna L., Green, Anna, Khan, Alesia, Knapper, Steve, Lambert, Jonathan, McGregor, Andrew, McMullin, Mary Frances, and Nangalia, Jyoti

Subjects
MYELOFIBROSIS, HEMATOLOGY, LOW-molecular-weight heparin, MYELOID metaplasia, WERNICKE'S encephalopathy, MEDICAL personnel
Abstract

This document is an update of the British Society for Haematology guideline on the management of myelofibrosis. It provides healthcare professionals with clear guidance on the stratified management of primary myelofibrosis, as well as post-polycythemia myelofibrosis and post-essential thrombocythemia myelofibrosis. The guidelines discuss various treatment options, including medications like ruxolitinib, fedratinib, momelotinib, and pacritinib, as well as other therapies such as hydroxycarbamide, pegylated interferons, and anti-platelet agents. The document also covers the management of MF-associated anemia, the use of erythropoiesis-stimulating agents, danazol, immunomodulating drugs, and iron chelation therapy. It provides recommendations for special situations and emphasizes the importance of individualized treatment approaches and patient support. Additionally, the document provides recommendations for pretransplant workup, donor choice, conditioning choice, and post allo-HSCT monitoring for patients considering allogeneic stem cell transplantation. [Extracted from the article]

Published
2024
Full Text
View/download PDF

22. Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.

Author

McLornan, Donal P., Godfrey, Anna L., Green, Anna, Frewin, Rebecca, Arami, Siamak, Brady, Jessica, Butt, Nauman M., Cargo, Catherine, Ewing, Joanne, Francis, Sebastian, Garg, Mamta, Harrison, Claire, Innes, Andrew, Khan, Alesia, Knapper, Steve, Lambert, Jonathan, Mead, Adam, McGregor, Andrew, Neelakantan, Pratap, and Psaila, Bethan

Subjects
MYELOFIBROSIS, HEMATOLOGY, DIAGNOSIS, PROGNOSIS, MEDICAL personnel, HEMATOPOIETIC stem cell transplantation
Abstract

This document is an update of the British Society for Haematology (BSH) guideline on myelofibrosis (MF), providing healthcare professionals with clear guidance on the diagnosis and prognostic evaluation of different types of MF. It emphasizes the importance of bone marrow biopsy and molecular testing for diagnosis, as well as the use of various prognostic models to inform clinical decisions and guide therapy. The document also discusses risk stratification and prognostication for MF patients, including the use of validated risk scores. Additionally, it provides information on the diagnosis and prognostication of prefibrotic MF, highlighting the importance of diagnostic criteria and mutational profiles. [Extracted from the article]

Published
2024
Full Text
View/download PDF

23. Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial

Author

Jackson, Graham H., Pawlyn, Charlotte, Cairns, David A., de Tute, Ruth M., Hockaday, Anna, Collett, Corinne, Jones, John R., Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D., Karunanithi, Kamaraj, Lindsay, Jindriska, Rocci, Alberto, Snowden, John A., Jenner, Matthew W., Cook, Gordon, Russell, Nigel H., Drayson, Mark T., Gregory, Walter M., Kaiser, Martin F., Owen, Roger G., Davies, Faith E., and Morgan, Gareth J.

Subjects
Drug therapy, Methods, Dosage and administration, Carfilzomib -- Dosage and administration, Cyclophosphamide -- Dosage and administration, Chemotherapy -- Methods, Multiple myeloma -- Drug therapy, Lenalidomide -- Dosage and administration, Dexamethasone -- Dosage and administration, Cancer -- Chemotherapy
Abstract

Author(s): Graham H. Jackson 1,*, Charlotte Pawlyn 2,3, David A. Cairns 4, Ruth M. de Tute 5, Anna Hockaday 4, Corinne Collett 4, John R. Jones 6, Bhuvan Kishore 7, [...], Background Carfilzomib is a second-generation irreversible proteasome inhibitor that is efficacious in the treatment of myeloma and carries less risk of peripheral neuropathy than first-generation proteasome inhibitors, making it more amenable to combination therapy. Methods and findings The Myeloma XI+ trial recruited patients from 88 sites across the UK between 5 December 2013 and 20 April 2016. Patients with newly diagnosed multiple myeloma eligible for transplantation were randomly assigned to receive the combination carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) or a triplet of lenalidomide, dexamethasone, and cyclophosphamide (Rdc) or thalidomide, dexamethasone, and cyclophosphamide (Tdc). All patients were planned to receive an autologous stem cell transplantation (ASCT) prior to a randomisation between lenalidomide maintenance and observation. Eligible patients were aged over 18 years and had symptomatic myeloma. The co-primary endpoints for the study were progression-free survival (PFS) and overall survival (OS) for KRdc versus the Tdc/Rdc control group by intention to treat. PFS, response, and safety outcomes are reported following a planned interim analysis. The trial is registered (ISRCTN49407852) and has completed recruitment. In total, 1,056 patients (median age 61 years, range 33 to 75, 39.1% female) underwent induction randomisation to KRdc (n = 526) or control (Tdc/Rdc, n = 530). After a median follow-up of 34.5 months, KRdc was associated with a significantly longer PFS than the triplet control group (hazard ratio 0.63, 95% CI 0.51-0.76). The median PFS for patients receiving KRdc is not yet estimable, versus 36.2 months for the triplet control group (p < 0.001). Improved PFS was consistent across subgroups of patients including those with genetically high-risk disease. At the end of induction, the percentage of patients achieving at least a very good partial response was 82.3% in the KRdc group versus 58.9% in the control group (odds ratio 4.35, 95% CI 3.19-5.94, p < 0.001). Minimal residual disease negativity (cutoff 4 x 10.sup.-5 bone marrow leucocytes) was achieved in 55% of patients tested in the KRdc group at the end of induction, increasing to 75% of those tested after ASCT. The most common adverse events were haematological, with a low incidence of cardiac events. The trial continues to follow up patients to the co-primary endpoint of OS and for planned long-term follow-up analysis. Limitations of the study include a lack of blinding to treatment regimen and that the triplet control regimen did not include a proteasome inhibitor for all patients, which would be considered a current standard of care in many parts of the world. Conclusions The KRdc combination was well tolerated and was associated with both an increased percentage of patients achieving at least a very good partial response and a significant PFS benefit compared to immunomodulatory-agent-based triplet therapy. Trial registration ClinicalTrials.gov ISRCTN49407852.

Published
2021
Full Text
View/download PDF

24. A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis.

Author

Ravichandran, Sriram, Hall, Andrew, Jenner, Matthew, Garg, Mamta, Kishore, Bhuvan, Lachmann, Helen, Gillmore, Julian, Pitchford, Alexandra, Oughton, Jamie B., Mahmood, Shameem, Sachchithantham, Sajitha, Hawkins, Philip, Brown, Sarah, and Wechalekar, Ashutosh

Subjects
IMMUNOGLOBULIN light chains, AMYLOIDOSIS, THALIDOMIDE, ACUTE kidney failure, MULTIPLE myeloma
Abstract

Proteasome inhibitors are the backbone of AL amyloidosis treatment – bortezomib being most widely used. Carfilzomib is a proteasome inhibitor licenced to treat multiple myeloma; autonomic and peripheral neuropathy are uncommon toxicities with carfilzomib. There is limited data on the use of carfilzomib in AL amyloidosis. Here, we report the results of a phase Ib dose-escalation study of Carfilzomib-Thalidomide-Dexamethasone (KTD) in relapsed/refractory AL amyloidosis. The trial registered 11 patients from 6 UK centres from September 2017 to January 2019; 10 patients received at least one dose of trial treatment. 80 adverse events were reported from 10 patients in the 1st three cycles. One patient experienced dose-limiting toxicity (acute kidney injury) at a dose of 45 mg/m2, and another patient had a SAR (fever). Five patients experienced an AE ≥ grade 3. There were no haematologic, infectious, or cardiac AE ≥ grade 3. The overall haematological response rate (ORR) at the end of three cycles of treatment was 60%. Carfilzomib 45 mg/m2 weekly can be safely given with thalidomide and dexamethasone. The efficacy and tolerability profile appears comparable to other agents in relapsed AL amyloidosis. These data provide a framework for further studies of carfilzomib combinations in AL amyloidosis. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial

Author

Striha, Alina, Ashcroft, A. John, Hockaday, Anna, Cairns, David A., Boardman, Karen, Jacques, Gwen, Williams, Cathy, Snowden, John A., Garg, Mamta, Cavenagh, Jamie, Yong, Kwee, Drayson, Mark T., Owen, Roger, Cook, Mark, and Cook, Gordon

Published
2018
Full Text
View/download PDF

26. Disease Characteristics and Outcomes of Non-Melanoma Skin Cancers in Myeloproliferative Neoplasm (MPN) Patients Treated with Ruxolitinib

Author

Rampotas, Alexandros, Carter-Brzezinski, Luke, Somervaille, Tim C.P, Forryan, James, Psaila, Bethan, Mead, Adam J, Garg, Mamta, Laing, Heather, Wallis, Louise, Butt, Nauman M, McConville, Conal, Sahra, Ali, McGregor, Andrew, Cowan, Hannah, Innes, Andrew J., Ewing, Joanne, Carter, Matthew, Dyer, Peter, Teh, Chun Huat, Francis, Sebastian, Wadelin, Frances, Harrison, Claire, Godfrey, Anna L, Kulakov, Elizabeth, McLornan, Donal P., and Lambert, Jonathan

Published
2022
Full Text
View/download PDF

27. Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study

Author

Mateos, Maria-Victoria, San-Miguel, Jesús, Cavo, Michele, Bladé Creixenti, Joan, Suzuki, Kenshi, Jakubowiak, Andrzej, Knop, Stefan, Doyen, Chantal, Lucio, Paulo, Nagy, Zsolt, Pour, Ludek, Grosicki, Sebastian, Crepaldi, Andre H, Liberati, Anna Marina, Campbell, Philip, Shelekhova, Tatiana, Yoon, Sung-Soo, Iosava, Genadi, Fujisaki, Tomoaki, Garg, Mamta, Pei, Huiling, Krevvata, Maria, Carson, Robin, Borgsten, Fredrik, and Dimopoulos, Meletios A.

Published
2022
Full Text
View/download PDF

28. Extended Intensified Post-ASCT Consolidation with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dara-VRd) for Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): The UK Optimum/Muknine Trial

Author

Kaiser, Martin F., Hall, Andrew, Smith, Isabelle, de Tute, Ruth M., Roberts, Sadie, Ingleson, Emma, Bowles, Kristian M, Garg, Mamta, Lokare, Anand, Messiou, Christina, Houlston, Richard S., Jackson, Graham, Cook, Gordon, Pratt, Guy, Drayson, Mark T, Owen, Roger G, Brown, Sarah R, and Jenner, Matthew W

Published
2022
Full Text
View/download PDF

29. Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Author

Harrison, Claire, Nangalia, Jyoti, Boucher, Rebecca H., Jackson, Aimee, Yap, Christina, O'Sullivan, Jennifer, Fox, Sonia, Ailts, Isaak, Dueck, Amylou C, Geyer, Holly L., Mesa, Ruben, Dunn, William, Nadezhdin, Eugene, Curto-Garcia, Natalia, Green, Anna, Wilkins, Bridget, Coppell, Jason, Laurie, John, Garg, Mamta, Ewing, Joanne, Knapper, Steve, Crowe, Josephine, Koutsavlis, Ioannis, Godfrey, Anna L, Arami, Siamak, Drummond, Mark W., Byrne, Jennifer, Clark, Fiona J, Mead-Harvey, Carolyn, Baxter, Joanna E, McMullin, Mary Frances, and Mead, Adam J

Published
2022
Full Text
View/download PDF

30. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

Author

Mateos, María-Victoria, Dimopoulos, Meletios A., Cavo, Michele, Suzuki, Kenshi, Jakubowiak, Andrzej, Knop, Stefan, Doyen, Chantal, Lucio, Paulo, Nagy, Zsolt, Kaplan, Polina, Pour, Ludek, Cook, Mark, Grosicki, Sebastian, Crepaldi, Andre, Liberati, Anna M., Campbell, Philip, Shelekhova, Tatiana, Yoon, Sung-Soo, Iosava, Genadi, Fujisaki, Tomoaki, Garg, Mamta, Chiu, Christopher, Wang, Jianping, Carson, Robin, Crist, Wendy, Deraedt, William, Nguyen, Huong, Qi, Ming, and San-Miguel, Jesus

Published
2018
Full Text
View/download PDF

32. Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.

Author

Kaiser, Martin F., Hall, Andrew, Walker, Katrina, Sherborne, Amy, De Tute, Ruth M., Newnham, Nicola, Roberts, Sadie, Ingleson, Emma, Bowles, Kristian, Garg, Mamta, Lokare, Anand, Messiou, Christina, Houlston, Richard S., Jackson, Graham, Cook, Gordon, Pratt, Guy, Owen, Roger G., Drayson, Mark T., Brown, Sarah R., and Jenner, Matthew W.

Published
2023
Full Text
View/download PDF

33. Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.

Author

Harrison, Claire N., Nangalia, Jyoti, Boucher, Rebecca, Jackson, Aimee, Yap, Christina, O'Sullivan, Jennifer, Fox, Sonia, Ailts, Isaak, Dueck, Amylou C., Geyer, Holly L., Mesa, Ruben A., Dunn, William G., Nadezhdin, Eugene, Curto-Garcia, Natalia, Green, Anna, Wilkins, Bridget, Coppell, Jason, Laurie, John, Garg, Mamta, and Ewing, Joanne

Published
2023
Full Text
View/download PDF

34. Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study

Author

Delimpasi, Sosana Mateos, Maria Victoria Auner, Holger W. and Gavriatopoulou, Maria Dimopoulos, Meletios A. Quach, Hang and Pylypenko, Halyna Hajek, Roman Leleu, Xavier Dolai, Tuphan Kanti Sinha, Dinesh Kumar Venner, Christopher P. Benjamin, Reuben Garg, Mamta Krishnan Doronin, Vadim Levy, Yair and Moreau, Philippe Chai, Yi Arazy, Melina Shah, Jatin and Shacham, Sharon Kauffman, Michael G. Richardson, Paul G. and Grosicki, Sebastian

Published
2022

35. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double‐blind, double‐dummy, symptom study (RELIEF)

Author

Mesa, Ruben, Vannucchi, Alessandro M., Yacoub, Abdulraheem, Zachee, Pierre, Garg, Mamta, Lyons, Roger, Koschmieder, Steffen, Rinaldi, Ciro, Byrne, Jennifer, Hasan, Yasmin, Passamonti, Francesco, Verstovsek, Srdan, Hunter, Deborah, Jones, Mark M., Zhen, Huiling, Habr, Dany, and Martino, Bruno

Published
2017
Full Text
View/download PDF

36. Rare cause of pericardial effusion: ‘ErdheimChester disease’.

Author

Imtiaz, Haider, Hussein, Mohsin, Chan, Daniel, and Garg, Mamta

Abstract

This report details the case of a woman in her 50s who presented with symptoms of congestive heart failure and raised inflammatory biochemical markers. Her investigations included an echocardiogram, which revealed a large pericardial effusion and a subsequent CT-thorax/abdomen/pelvis showing extensive retroperitoneal, pericardial and periaortic inflammation and soft-tissue infiltration. Genetic analysis of histopathological samples detected a V600E or V600Ec missense variant within codon 600 of the BRAF genewith BRAF variants, confirming the diagnosis of ErdheimChester disease (ECD). The patient’s clinical management involved several treatments and interventions with input from a variety of clinical specialties. This included the cardiology team for pericardiocentesis, the cardiac surgical team for pericardiectomy due to recurrent pericardial effusions and finally the haematology team for further specialist treatment with pegylated interferon and consideration of BRAF inhibitor therapy. The patient became stable following treatment with significant improvement in her heart failure symptoms. She remains under regular joint cardiology and haematology team follow-up. The case highlighted the importance of using a multidisciplinary approach to best manage the multisystem involvement of ECD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

38. Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone

Author

Sanchez, Larysa, Leleu, Xavier, Beaumont, Jennifer, Yu, Hailin, Hudgens, Stacie, Auner, Holger W, Quach, Hang, Delimpasi, Sosana, Spicka, Ivan, Pour, Luděk, Dimopoulos, Meletios A, Pylypenko, Halyna, Doronin, Vadim A, Usenko, Ganna, Hajek, Roman, Benjamin, Reuben, Venner, Christopher P., Garg, Mamta, Stevens, Don A., Jagannath, Sundar, Moreau, Philippe, Levy, Moshe, Bahlis, Nizar J., Facon, Thierry, Chai, Yi, Ma, Xiwen, Tang, Shijie, Leong, Hoyee, Shah, Jatin J., Shacham, Sharon, Kauffman, Michael G, Richardson, Paul G., and Grosicki, Sebastian

Published
2020
Full Text
View/download PDF

39. Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study

Author

Mateos, Maria, Jagannath, Sundar, Delimpasi, Sosana, Simonova, Maryana, Spicka, Ivan, Pour, Ludek, Kryachok, Irina, Gavriatopoulou, Maria, Dimopoulos, Meletios A, Pylypenko, Halyna, Auner, Holger W, Leleu, Xavier, Doronin, Vadim A, Usenko, Ganna, Benjamin, Reuben, Dolai, Tuphan Kanti, Sinha, Dinesh Kumar, Venner, Christopher P., Garg, Mamta, Stevens, Don A., Quach, Hang, Moreau, Philippe, Levy, Moshe Y., Badros, Ashraf Z., Anderson, Larry D., Jr., Bahlis, Nizar J., Facon, Thierry, Cavo, Michele, Chai, Yi, Arazy, Melina, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G, Richardson, Paul G., and Grosicki, Sebastian

Published
2020
Full Text
View/download PDF

40. Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study

Author

Mateos, Maria, Gavriatopoulou, Maria, Facon, Thierry, Auner, Holger W, Leleu, Xavier, Hajek, Roman, Dimopoulos, Meletios A, Delimpasi, Sosana, Simonova, Maryana, Spicka, Ivan, Pour, Ludek, Kryachok, Irina, Pylypenko, Halyna, Doronin, Vadim A, Usenko, Ganna, Benjamin, Reuben, Dolai, Tuphan Kanti, Sinha, Dinesh Kumar, Venner, Christopher P., Garg, Mamta, Stevens, Don A., Quach, Hang, Jagannath, Sundar, Moreau, Philippe, Levy, Moshe, Badros, Ashraf Z., Anderson, Larry D., Jr., Bahlis, Nizar J., Cavo, Michele, Chai, Yi, Arazy, Melina, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G, Richardson, Paul G., and Grosicki, Sebastian

Published
2020
Full Text
View/download PDF

41. Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study

Author

Facon, Thierry Auner, Holger W. Gavriatopoulou, Maria and Delimpasi, Sosana Simonova, Maryana Spicka, Ivan Pour, Ludek and Dimopoulos, Meletios A. Kriachok, Iryna Pylypenko, Halyna and Leleu, Xavier Quach, Hang Reuben, Benjamin Dolai, Tuphan Kanti Sinha, Dinesh Kumar Garg, Mamta Stevens, Don A. and Shah, Jatin J. Richardson, Paul G. Grosicki, Sebastian

Published
2021

42. Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma

Author

Leleu, Xavier Mateos, Maria-Victoria Jagannath, Sundar and Delimpasi, Sosana Simonova, Maryana Spicka, Ivan Pour, Ludek and Kriachok, Iryna Gavriatopoulou, Maria Dimopoulos, Meletios A. Pylypenko, Halyna Auner, Holger W. Reuben, Benjamin and Venner, Christopher P. Garg, Mamta DeCastro, Andrew Shah, Jatin J. Grosicki, Sebastian Richardson, Paul G.

Published
2021

43. Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone

Author

Sanchez, Larysa Leleu, Xavier Beaumont, Jennifer L. Yu, Hailin Hudgens, Stacie Simonova, Maryana Auner, Holger W. and Quach, Hang Delimpasi, Sosana Spicka, Ivan Pour, Ludek and Kriachok, Iryna Dimopoulos, Meletios A. Usenko, Ganna and Hajek, Roman Benjamin, Reuben Sinha, Dinesh Kumar Venner, Christopher Illmer, Thomas Garg, Mamta Krishnan Stevens, Don Ambrose Jagannath, Sundar Levy, Moshe Anderson, Jr., Larry D. Bahlis, Nizar Jacques Facon, Thierry Cavo, Michele and Chai, Yi Ma, Xiwen Tang, Shijie Leong, Hoyee Shah, Jatin and Shacham, Sharon Kauffman, Michael Richardson, Paul and Grosicki, Sebastian

Published
2021

45. Ixazomib-Based Consolidation and Maintenance Prolongs Progression-Free Survival after Salvage Autologous Stem Cell Transplantation (sASCT): Results from Interim Analysis of UK-MRA Myeloma XII (ACCoRD)

Author

Cook, Gordon, Ashcroft, A J, Senior, Ethan R, Olivier, Catherine, Hockaday, Anna, Richards, Jeanine, Cavenagh, James D., Snowden, John, Drayson, Mark, de Tute, Ruth M, Owen, Roger, Yong, Kwee, Garg, Mamta, Boyd, Kevin, Sati, Hamdi, Gillson, Sharon, Cook, Mark, Cairns, David Allan, and Parrish, Christopher

Published
2023
Full Text
View/download PDF

46. Initial Report of Part B Phase 1/2 Efficacy and Safety Results for Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Relapsed Immune Thrombocytopenia

Author

Cooper, Nichola, Jansen, A.J. Gerard, Bird, Robert, Mayer, Jiří, Sholzberg, Michelle, Tarantino, Michael D., Garg, Mamta, Ypma, Paula F, McDonald, Vickie, Percy, Charles, Košťál, Milan, Goncalves, Isaac, Bogdanov, Lachezar H., Gernsheimer, Terry B, Diab, Remco, Yao, Mengjie, Daak, Ahmed, and Kuter, David J

Published
2023
Full Text
View/download PDF

47. High Responses Rates with Single Agent Belantamab Mafodotin in Relapsed Systemic AL Amyloidosis

Author

Khwaja, Jahanzaib, Bomsztyk, Joshua, Bygrave, Ceri, Forbes, Adam, Durairaj, Senthilkumar, Fernandes, Savio, Taylor, James, Paterson, Pamela, Brearton, Gillian, Crawley, Charles, Sheehy, Oonagh, Brown, Rachel, Soutar, Richard, Garg, Mamta, Rydzewski, Andrzej, Jamroziak, Krzysztof, Dowling, Emma, Correia, Nuno, Worthington, Sarah, Mahmood, Shameem, and Wechalekar, Ashutosh D.

Published
2023
Full Text
View/download PDF

48. P-110 Ixazomib maintenance in transplant-ineligible patients with newly diagnosed multiple myeloma: final overall survival analysis from the TOURMALINE-MM4 study

Author

Dimopoulos, Meletios, Chng, Wee Joo, Iida, Shinsuke, Mateos, Maria-Victoria, Morgan, Gareth, Lonial, Sagar, Špička, Ivan, Quach, Hang, Oriol, Albert, Hájek, Roman, Garg, Mamta, Giuliani, Nicola, Beksac, Meral, Katodritou, Eirini, Bringhen, Sara, Li, Cong, Zhang, Xiaoquan, Labotka, Richard, and Rajkumar, Vincent

Published
2023
Full Text
View/download PDF

50. British Society for Haematology guidelines for the laboratory diagnosis of malaria.

Author

Rogers, Claire L., Bain, Barbara J., Garg, Mamta, Fernandes, Savio, Mooney, Ciaran, and Chiodini, Peter L.

Subjects
CLINICAL pathology, MALARIA, HEMATOLOGY, DIFFERENTIAL diagnosis, DIAGNOSIS methods
Abstract

Copyright of British Journal of Haematology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results